Clinical trial
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in…
NCT00358566 · Pharmexa A/S, Industry · Terminated
Key facts
| NCT number | NCT00358566 |
|---|---|
| Title | GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer |
| Official title | "Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer. |
| Lead sponsor | Pharmexa A/S, Industry |
| Collaborators | ICON Clinical Research Industry ORION Clinical Services CIRION Central Laboratory Dorevitch Syneos Health |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Unresectable Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | GV1001, Gemcitabine (Chemotherapy) |
| Enrollment | 360 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Aug 1, 2006 |
| Last update posted | May 19, 2008 |
| Countries | Australia, Belgium, Denmark, France, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: